Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HOLX vs HSIC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HOLX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

HOLX Overall Winner 6-Pillar Tally: HOLX 3 – 3 HSIC Matrix Metrics: HOLX 7 – 3 HSIC

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Henry Schein Inc (HSIC) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas HSIC carries 50.9/100 (HOLD) at $83.52 (13.9x Forward P/E, 5.8% operating margin).

  • Technical & Structure Timing Caution: HOLX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 69.0); meanwhile HSIC is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HOLX vs HSIC
HOLX NASDAQ Head-to-Head Winner
Hologic Inc
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$76.01
+0.48% 1D
Market Cap $16.9B
TTM Revenue $4.13B
Forward P/E 20.1x
Beta / 30D Vol 0.08β · 3% Vol
Unified Composite Score
64.2 / 100 BUY
Tech 75.0 Fund 61.0 Flow 54.0 Mom 49.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 69.0 · SMA20: $75.47 · SMA50: $75.29
HSIC NASDAQ
Henry Schein Inc
Wholesale-Medical, Dental & Hospital Equipment & Supplies
$83.52
-1.51% 1D
Market Cap $9.4B
TTM Revenue $13.7B
Forward P/E 13.9x
Beta / 30D Vol 0.55β · 40% Vol
Unified Composite Score
50.9 / 100 HOLD
Tech 50.0 Fund 53.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.7%) with fading momentum, RSI 45
RSI-14: 44.5 · SMA20: $85.68 · SMA50: $85.50

6-Pillar Scorecard Institutional Category Breakdown (HOLX 3 – 3 HSIC)

Columns: Metric · HOLX · HSIC
1. Valuation Multiples HSIC
Forward P/E 20.1x 13.9x
Trailing P/E 31.4x 23.2x
PEG Ratio 1.66x 1.67x
EV / Revenue 4.1x 1.0x
2. Growth & Scale HSIC
Revenue Growth (YoY) +2.5% +4.0%
Earnings Growth (YoY) -9.2% +26.2%
TTM Revenue (USD) $4.13B $13.7B
Market Cap $16.9B $9.4B
3. Profitability & Quality HOLX
Gross Margin 60.4% 31.6%
Operating Margin 23.0% 5.8%
Net Profit Margin 13.2% 3.1%
Return on Equity (ROE) 10.9% 9.2%
4. Balance Sheet & Cash Flow HOLX
Cash Generation (TTM) $1.35B EBITDA $500M
Cash Flow Margin 32.7% EBITDA Mgn 3.6%
Net Cash / Leverage $23.51 Book/Sh · 10.9% ROE $3.71B Net Debt (1.23x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HSIC
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 6.3% (3rd %ile) 29.4% (8th %ile)
Put/Call OI Skew 6.20x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Distribution
6. R&D & Supply-Chain Moat HOLX
OpEx & R&D Intensity 37.4% of Rev ($1.54B) 25.8% of Rev ($3.54B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Distribution Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HOLX (7) vs HSIC (3)
Institutional Metric HOLX HSIC Criterion Row Edge
Market Capitalization
Scale
$16.9B $9.4B Larger Scale HOLX
Trailing P/E Ratio
Valuation
31.4x 23.2x Lower Multiple HSIC
Forward P/E Ratio
Valuation
20.1x 13.9x Lower Multiple HSIC
Revenue Growth (YoY)
Growth
+2.5% +4.0% Higher Growth HSIC
Operating Margin (TTM)
Profitability
23.0% 5.8% Higher Margin HOLX
Net Profit Margin
Profitability
13.2% 3.1% Higher Margin HOLX
Return on Equity (ROE)
Capital Efficiency
10.9% 9.2% Higher ROE HOLX
52-Week Range Position
Momentum
100% ($52–$76) 63% ($69–$92) Stronger Trend HOLX
Beta / 30D Volatility
Risk Regime
0.08β · 3% Vol 0.55β · 40% Vol Lower Realized Risk HOLX
Unified Institutional Score
Composite Signal
64.2 / 100 (BUY) 50.9 / 100 (HOLD) Higher Composite HOLX
Trailing 12M Revenue (USD)
Operating Scale
$4.13B $13.7B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.4% 31.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.66x PEG · 4.1x EV/Rev 1.67x PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.35B EBITDA ($23.51 Book/Sh · 10.9% ROE) $500M ($3.71B Net Debt (1.23x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HOLX +6.96 pp
HOLX: +0.34% · HSIC: -6.62%
3M Horizon HOLX +4.49 pp
HOLX: +1.94% · HSIC: -2.55%
6M Horizon HSIC +3.55 pp
HOLX: +2.48% · HSIC: +6.03%
1Y Horizon HSIC +3.55 pp
HOLX: +2.48% · HSIC: +6.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HOLX vs HSIC. Trailing 12-month operating profitability (HOLX 23.0% vs HSIC 5.8%) and valuation multiples (HOLX 20.1x vs HSIC 13.9x Forward P/E) are benchmarked directly in Pillar 4 below.

HOLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.13B
Gross Margin60.4%
Op. Margin23.0%
ROE / Fwd P/E10.9% · 20.1x
HSIC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13.7B
Gross Margin31.6%
Op. Margin5.8%
ROE / Fwd P/E9.2% · 13.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HOLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 6.3%
IV Percentile 3rd %ile
Put/Call OI Skew 6.20x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact HOLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HSIC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 29.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact HSIC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HOLX Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment 37.4% of Rev ($1.54B)
90D Engineering Disclosures 0 Published
HSIC Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $9.4B market capitalization and 5.8% operating margin.
OpEx & R&D Reinvestment 25.8% of Rev ($3.54B)
90D Engineering Disclosures 0 Published

Investor FAQ HOLX vs HSIC Key Questions & Quantitative Answers

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Henry Schein Inc (HSIC) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas HSIC carries 50.9/100 (HOLD) at $83.52 (13.9x Forward P/E, 5.8% operating margin). Technical & Structure Timing Caution: HOLX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 69.0); meanwhile HSIC is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HSIC leads the Growth & Scale pillar: HOLX posts +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin), compared with HSIC at +4.0% YoY revenue growth and +26.2% YoY earnings growth on $13.7B TTM revenue (31.6% gross margin, 5.8% operating margin). On trailing 12-month operating scale, HOLX generates $4.13B in USD-normalized revenue versus $13.7B for HSIC. In operating R&D and SG&A reinvestment, HOLX deploys 37.4% of Rev ($1.54B) (0 90-day corporate R&D disclosures) versus 25.8% of Rev ($3.54B) (0 disclosures) for HSIC.

HSIC screens cheaper on headline valuation multiples. HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin), whereas HSIC trades at 13.9x Forward P/E, 23.2x Trailing P/E, 1.67x PEG, and 1.0x EV/Revenue (3.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HOLX (10.9% ROE) versus HSIC (9.2% ROE) capital efficiency.

In options market volatility and institutional positioning, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk). By comparison, HSIC carries 29.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.55β · 40% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.